Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer

ConclusionThe provision of genetic testing to high-risk women with a BRCA1 and two mutation probability of ≥ 10% based on the individual family cancer history appears to be a cost-effective option for the SHI.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research